Medindia

X

Sequenom, Inc. Reports Financial Results for the First Quarter of 2011

Friday, May 6, 2011 General News J E 4
Advertisement
Company Announces Completion Of Pivotal Clinical Validation Study For SensiGene Trisomy 21 Laboratory Developed Test

SEQUENOM, INC.

CONDENSED CONSOLIDATED BALANCE SHEETS

(unaudited)

(in thousands except for par value and share information)

March 31,2011

December 31,2010

Assets:

Cash, cash equivalents, marketable securities

$     125,268

$      135,480

Restricted cash

76

1,404

Accounts receivable, net

6,827

6,911

Inventories, net

5,380

5,605

Other current assets and prepaid expenses

2,576

2,387

Total current assets

140,127

151,787

Equipment and leasehold improvements, net

11,108

11,038

Other assets

11,365

11,454

Total assets

$     162,600

$      174,279

Liabilities and Stockholders' Equity:

Accounts payable

$         5,500

$          5,958

Accrued expenses and current liabilities

7,752

9,947

Deferred revenue

3,121

2,624

Current portion of debt and obligations

906

938

Total current liabilities

17,279

19,467

Long-term liabilities

3,802

4,080

Stockholders' equity

141,519

150,732

Total liabilities and stockholders' equity

$     162,600

$      174,279

Advertisement


Advertisement

You May Also Like

Advertisement
View All

Post your Comments

Comments should be on the topic and should not be abusive. The editorial team reserves the right to review and moderate the comments posted on the site.
User Avatar
* Your comment can be maximum of 2500 characters
I agree to the terms and conditions
s
HeartWare International Reports First Quarter 2011...
S
IRIDEX Reports Growing Revenue and Profits in 2011...